MENU
CANC
ETF ticker: NASDAQ
PRICE
CHANGE
NET ASSETS

CANC stock forecast, quote, news & analysis

The investment seeks to provide long-term growth... Show more

Category: #Health
CANC
Daily Signal:
Gain/Loss:
A.I.Advisor
published price charts
Interact to see
Advertisement
A.I.Advisor
a Summary for CANC with price predictions
Sep 11, 2026

CANC in downward trend: price dove below 50-day moving average on September 10, 2026

CANC moved below its 50-day moving average on September 10, 2026 date and that indicates a change from an upward trend to a downward trend. In 28 of 33 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 85%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for CANC moved out of overbought territory on August 20, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 15 similar instances where the indicator moved out of overbought territory. In 11 of the 15 cases, the stock moved lower in the following days. This puts the odds of a move lower at 73%.

The Momentum Indicator moved below the 0 level on September 04, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CANC as a result. In 37 of 53 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 70%.

The Moving Average Convergence Divergence Histogram (MACD) for CANC turned negative on August 28, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 27 similar instances when the indicator turned negative. In 22 of the 27 cases the stock turned lower in the days that followed. This puts the odds of success at 81%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CANC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.

Bullish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.

Following a +1.56% 3-day Advance, the price is estimated to grow further. Considering data from situations where CANC advanced for three days, in 165 of 187 cases, the price rose further within the following month. The odds of a continued upward trend are 88%.

CANC may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In 129 of 145 cases where CANC Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 89%.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), ABBVIE (NYSE:ABBV), Merck & Co (NYSE:MRK), AstraZeneca PLC (NYSE:AZN), Amgen (NASDAQ:AMGN), Gilead Sciences (NASDAQ:GILD), Bristol-Myers Squibb Co (NYSE:BMY), Regeneron Pharmaceuticals (NASDAQ:REGN), Illumina (NASDAQ:ILMN), Incyte Corp (NASDAQ:INCY).

Industry description

The investment seeks to provide long-term growth. Under normal circumstances, the fund seeks to achieve its investment objective by investing at least 80% of its net assets, which include borrowings for investment purposes, in publicly listed companies that derive at least 50% of revenues from oncology. The fund is non-diversified.

Market Cap

The average market capitalization across the Tema Oncology ETF ETF is 61.43B. The market cap for tickers in the group ranges from 3.51M to 994.49B. LLY holds the highest valuation in this group at 994.49B. The lowest valued company is NOVN at 3.51M.

High and low price notable news

The average weekly price growth across all stocks in the Tema Oncology ETF ETF was -6%. For the same ETF, the average monthly price growth was -4%, and the average quarterly price growth was 15%. MREO experienced the highest price growth at 12%, while RCUS experienced the biggest fall at -17%.

Volume

The average weekly volume growth across all stocks in the Tema Oncology ETF ETF was 32%. For the same stocks of the ETF, the average monthly volume growth was -6% and the average quarterly volume growth was -17%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 54
P/E Growth Rating: 66
Price Growth Rating: 40
SMR Rating: 78
Profit Risk Rating: 74
Seasonality Score: -19 (-100 ... +100)
View a ticker or compare two or three
CANC
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Category Health

Profile
Details
Category
Health
Address
United Satets
Phone
N/A
Web
www.tema.co
CANC in downward trend: price dove below 50-day moving average on September 10, 2026